Advanced Catheter Therapies

Advanced Catheter Therapies, Inc. (ACT) is a research and development medical device company with a portfolio of innovative catheter technologies targeting vascular disease including thrombosis, inflammation, occlusions and restenosis.

ACT has initially focused its resources on the problem of restenosis and has developed the 510(k) cleared and patented Occlusion Perfusion Catheter™ (OPC). The OPC is a multi‐lumen balloon catheter designed to temporarily occlude a specific region from blood flow to allow the local delivery of therapeutic agents to the peripheral and coronary vasculature. The OPC should be available for commercial purchase for use in delivering anti-restenosis agents in Q1 2017 from ACT's licensee, Toray Industries.

Also in the development pipeline are devices to improve endovascular debulking procedures (the clearing of blocked blood vessels).


Advanced Catheter Therapies Receives Third FDA 510(k) Clearance on Occlusion Perfusion Catheter®
CHATTANOOGA, TN, December 1, 2016 – Advanced Catheter Therapies, Inc. (ACT), today announced that its Occlusion Perfusion Catheter™ (OPC) has received a third 501(k) clearance from the U.S. Food and Drug Administration (FDA). This new indication allows the OPC, a universal targeted therapeutic agent delivery catheter, to be repositioned for the delivery of various agents for multiple treatments with the same patient. Current treatments for restenosis may require the use of multiple devices such a drug-coated balloon or drug-coated stent for the same patient.
“The ability to deploy the OPC multiple times for the same patient not only saves money by reducing the number of catheters required, it adds even more control and versatility for the clinician and has the potential to streamline the delivery of treatments for restenosis and other diseases such as AV fistulas, targeted cancer therapies, lytic therapies and venous insufficiencies,” said Paul Fitzpatrick, CEO of ACT.

Read more